Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities

[1]  M. Cheminant,et al.  Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells , 2021, Haematologica.

[2]  S. Chambeyron,et al.  In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ , 2021, PLoS pathogens.

[3]  R. Nasr,et al.  Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma , 2020, Frontiers in Microbiology.

[4]  K. Tsukasaki,et al.  Novel Treatments of Adult T Cell Leukemia Lymphoma , 2020, Frontiers in Microbiology.

[5]  L. Frenzel,et al.  Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma , 2020, Retrovirology.

[6]  P. Kaesberg,et al.  Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies , 2020, Leukemia & lymphoma.

[7]  P. Afonso,et al.  Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes , 2019, Retrovirology.

[8]  K. Nakano,et al.  Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. , 2019, Cell reports.

[9]  K. Ono,et al.  Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy , 2019, Leukemia research reports.

[10]  J. Okamura,et al.  Maintenance of long remission in adult T‐cell leukemia by Tax‐targeted vaccine: A hope for disease‐preventive therapy , 2019, Cancer science.

[11]  Zhen-dong Yu,et al.  Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas , 2019, International journal of medical sciences.

[12]  T. Waldmann,et al.  Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[14]  S. Horwitz,et al.  Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma , 2018, Haematologica.

[15]  L. Ratner.  PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma. , 2018, The New England journal of medicine.

[16]  A. Utsunomiya,et al.  PD-1 Inhibitor Therapy in Adult T-Cell Leukemia–Lymphoma. , 2018, The New England journal of medicine.

[17]  C. Bangham.  Human T Cell Leukemia Virus Type 1: Persistence and Pathogenesis. , 2018, Annual review of immunology.

[18]  N. Darwiche,et al.  Mouse Models That Enhanced Our Understanding of Adult T Cell Leukemia , 2018, Front. Microbiol..

[19]  G. Barber,et al.  Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. , 2018, Blood advances.

[20]  G. Taylor,et al.  Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infection , 2018, PLoS pathogens.

[21]  M. Matsuoka,et al.  Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells , 2018, Proceedings of the National Academy of Sciences.

[22]  G. Forlani,et al.  HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases , 2017, Front. Microbiol..

[23]  A. Hasegawa,et al.  IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways , 2017, PLoS pathogens.

[24]  S. Grelli,et al.  Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. , 2017, Blood advances.

[25]  M. Ogura,et al.  Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Steinberg,et al.  Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma , 2016, Clinical Cancer Research.

[27]  O. J. Semmes,et al.  HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma—A Tale of Two Proteins: Tax and HBZ , 2016, Viruses.

[28]  K. Nakano,et al.  Polycomb-dependent epigenetic landscape in adult T-cell leukemia. , 2016, Blood.

[29]  M. Ogura,et al.  Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. , 2016, The Lancet. Haematology.

[30]  Yutaka Suzuki,et al.  HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT) , 2016, PLoS pathogens.

[31]  S. Hanada,et al.  Treatment and survival among 1594 patients with ATL. , 2015, Blood.

[32]  M. Matsuoka,et al.  Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. , 2015, Blood.

[33]  R. Mahieux,et al.  A Transgenic Drosophila melanogaster Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1-Driven Transformation In Vivo , 2015, Journal of Virology.

[34]  K. Akashi,et al.  Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study , 2015, British journal of haematology.

[35]  R. Ueda,et al.  Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.

[36]  Y. Kfoury,et al.  ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. , 2015, Blood.

[37]  T. Waldmann,et al.  Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model , 2014, Leukemia.

[38]  A. Ghavamzadeh,et al.  The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma , 2013, Retrovirology.

[39]  Y. Kfoury,et al.  Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation , 2013, Front. Microbiol..

[40]  S. Kinpara,et al.  Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells , 2013, Retrovirology.

[41]  S. Akinaga,et al.  Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas , 2012, Current Hematologic Malignancy Reports.

[42]  Makoto Yamagishi,et al.  Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. , 2012, Cancer cell.

[43]  K. Tobinai,et al.  Clinical Trials and Treatment of ATL , 2012, Leukemia research and treatment.

[44]  S. Montoto,et al.  Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Chen,et al.  Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. , 2011, Leukemia research.

[46]  M. Azarpazhooh,et al.  High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[47]  A. Lézin,et al.  Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes. , 2011, Blood.

[48]  A. Bazarbachi,et al.  How I treat adult T-cell leukemia/lymphoma. , 2011, Blood.

[49]  I. Lossos,et al.  Newly Emerging Therapies Targeting Viral-Related Lymphomas , 2011, Current oncology reports.

[50]  A. Gessain.  [Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases]. , 2011, Bulletin de la Societe de pathologie exotique.

[51]  H. Shih,et al.  NF-κB hyper-activation by HTLV-1 Tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ , 2011, Retrovirology.

[52]  R. Nasr,et al.  Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects? , 2011, Viruses.

[53]  H. Mano,et al.  Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy , 2011, Haematologica.

[54]  大介 佐々木.  Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy , 2011 .

[55]  H. Shih,et al.  NF-κB Hyper-Activation by HTLV-1 Tax Induces Cellular Senescence, but Can Be Alleviated by the Viral Anti-Sense Protein HBZ , 2011, PLoS pathogens.

[56]  K. Jeang,et al.  Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy , 2011, Oncogene.

[57]  N. Mori,et al.  LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway , 2011, Leukemia.

[58]  A. Saïb,et al.  Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome , 2011, Retrovirology.

[59]  R. Mahfouz,et al.  Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia , 2010, The Journal of experimental medicine.

[60]  R. Mahieux,et al.  Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. , 2010, Blood.

[61]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  K. Matsuo,et al.  Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. , 2010, Blood.

[64]  K. Tobinai.  Current management of adult T-cell leukemia/lymphoma. , 2009, Oncology.

[65]  E. Wattel,et al.  Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). , 2009, Blood.

[66]  M. Nakao,et al.  Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. , 2009, Blood.

[67]  L. Ratner,et al.  Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. , 2009, Blood.

[68]  J. Sparano,et al.  Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma , 2009, PloS one.

[69]  T. Waldmann,et al.  Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. , 2009, Blood.

[70]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Y. Takatsuka,et al.  Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation , 2008, Bone Marrow Transplantation.

[73]  R. Nasr,et al.  Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome , 2008, Oncogene.

[74]  H. Koeffler,et al.  Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB , 2008 .

[75]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Tomonaga,et al.  Long-term study of indolent adult T-cell leukemia-lymphoma. , 2007, Blood.

[77]  C. Brites,et al.  Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. , 2007, American journal of clinical pathology.

[78]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  G. Dbaibo,et al.  Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. , 2007, Haematologica.

[80]  Anne-Mieke Vandamme,et al.  Human T-lymphotropic virus 1: recent knowledge about an ancient infection. , 2007, The Lancet. Infectious diseases.

[81]  Kuan-Teh Jeang,et al.  Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation , 2007, Nature Reviews Cancer.

[82]  A. Shirdel,et al.  Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran , 2007, Leukemia & lymphoma.

[83]  T. Waldmann,et al.  Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. , 2006, Blood.

[84]  R. Mahieux,et al.  Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. , 2006, Blood.

[85]  T. Ichinohe,et al.  Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I , 2006, Nature Medicine.

[86]  M. Tomonaga,et al.  Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma , 2005, Leukemia.

[87]  Olivier Hermine,et al.  New therapeutic approaches for adult T-cell leukaemia. , 2004, The Lancet. Oncology.

[88]  M. Tomonaga,et al.  Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells , 2004, Journal of Virology.

[89]  R. Nasr,et al.  Human T-Cell Lymphotropic Virus Type I-Infected Cells Extravasate through the Endothelial Barrier by a Local Angiogenesis-Like Mechanism , 2004, Cancer Research.

[90]  I. Moura,et al.  A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients , 2004, Retrovirology.

[91]  Olivier Hermine,et al.  Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. , 2003, Blood.

[92]  M. Tomonaga,et al.  Deoxycoformycin-Containing Combination Chemotherapy for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study (JCOG9109) , 2003, International journal of hematology.

[93]  M. Biard-Piechaczyk,et al.  The Complementary Strand of the Human T-Cell Leukemia Virus Type 1 RNA Genome Encodes a bZIP Transcription Factor That Down-Regulates Viral Transcription , 2002, Journal of Virology.

[94]  M. El-Sabban,et al.  Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. , 2002, Blood.

[95]  J. Cavenagh,et al.  Interferon α and zidovudine therapy in adult T‐cell leukaemia lymphoma: response and outcome in 15 patients , 2001, British journal of haematology.

[96]  M. Tomonaga,et al.  A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.

[97]  T. Waldmann,et al.  The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma , 2001, Leukemia & lymphoma.

[98]  G. Dbaibo,et al.  Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma , 2000, Leukemia.

[99]  J. Weber,et al.  Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. , 2000, Blood.

[100]  L. Ratner,et al.  Immortalization of CD4+ and CD8+ T Lymphocytes by Human T-Cell Leukemia Virus Type 1 Tax Mutants Expressed in a Functional Molecular Clone , 1999, Journal of Virology.

[101]  M. Tomonaga,et al.  An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[102]  K. Shimotohno,et al.  Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. , 1995, Blood.

[103]  M. Kaplan,et al.  Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. , 1995, The New England journal of medicine.

[104]  E. Macintyre,et al.  Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa , 1995 .

[105]  S. Wain-Hobson,et al.  Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy , 1995, Journal of virology.

[106]  W. Sheremata,et al.  Clinical spectrum of HTLV-I in south Florida. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[107]  T. Ley,et al.  Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[108]  Y. Ohashi,et al.  Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. , 1994, British Journal of Cancer.

[109]  D. Catovsky,et al.  Deoxycoformycin in the treatment of mature T-cell leukaemias. , 1991, British Journal of Cancer.

[110]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[111]  T. Andoh,et al.  Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. , 1991, Cancer research.

[112]  H. Inoko,et al.  Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. , 1991, International immunology.

[113]  A. Fauci,et al.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease , 1990, Nature.

[114]  Michael Frank Harris,et al.  Lymphoma , 1990, BMJ : British Medical Journal.

[115]  S. Yamaoka,et al.  Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[116]  M. Shimoyama.  [Recent progress in non-Hodgkin's lymphoma study in Japan]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

[117]  R. K. Reynolds,et al.  The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. , 1987, Science.

[118]  M. Osame.  [HTLV-I-associated myelopathy]. , 1987, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[119]  G. de‐Thé,et al.  HTLV-I AND TROPICAL SPASTIC PARAPARESIS IN AFRICA , 1986, The Lancet.

[120]  W. Blattner,et al.  Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. , 1983, The New England journal of medicine.

[121]  M. Greaves,et al.  ADULT T-CELL LYMPHOMA-LEUKAEMIA IN BLACKS FROM THE WEST INDIES , 1982, The Lancet.

[122]  M. Reitz,et al.  Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia , 1981, Nature.

[123]  J. Yodoi,et al.  [Surface markers of malignant lymphoid cells in the classification of lymphoproliferative disorders, with special reference to adult T-cell leukemia (author's transl)]. , 1976, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[124]  A. Bazarbachi,et al.  Corrigendum to 'Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis' [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[125]  A. Nagler,et al.  Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP , 2014, Bone Marrow Transplantation.

[126]  安間恵子,et al.  HTLV－1 bZIP factorが誘導する免疫抑制の機序 , 2014 .

[127]  Youmna Kfoury,et al.  The multifaceted oncoprotein Tax: subcellular localization, posttranslational modifications, and NF-κB activation. , 2012, Advances in cancer research.

[128]  C. Bangham,et al.  How does HTLV-I persist despite a strong cell-mediated immune response? , 2008, Trends in immunology.

[129]  A. Renand,et al.  Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody , 2008, Leukemia.

[130]  H. Koeffler,et al.  Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. , 2008, Leukemia research.

[131]  Y. Kanda,et al.  Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[132]  H. Dombret,et al.  Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. , 2004, The hematology journal : the official journal of the European Haematology Association.

[133]  A. Bazarbachi,et al.  A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. , 2002, The hematology journal : the official journal of the European Haematology Association.

[134]  Y. Kodera,et al.  Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[135]  G. Dbaibo,et al.  Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. , 2000, Blood.

[136]  R. Nasr,et al.  Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. , 1999, Blood.

[137]  A. Bazarbachi,et al.  Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[138]  T. Waldmann,et al.  The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. , 1993, Blood.